Clinical Trial

A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH

Name: A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH — clinical trial record (NCT07625280)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: XYRISE

Not Yet Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The purpose of this study is to evaluate the efficacy and safety of expanded Xywav dosing regimens in adult participants with narcolepsy or idiopathic hypersomnia (IH).

Trial Details

NCT Number	NCT07625280
Lead Sponsor	Jazz Pharmaceuticals Collaborators: Jazz Pharmaceuticals Ireland Limited
Conditions	Narcolepsy, Idiopathic Hypersomnia
Enrollment	108 participants
Start Date	2026-06-30
Primary Completion	2027-12-23 (estimated)
Study Completion	2028-01-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-04